Robotic-assisted and laparoscopic liver resection yield better outcomes for BCLC stage 0/A hepatocellular carcinoma compared to open surgery. Operative times were longer for robotic (225 min) and laparoscopic (225 min) than for open (170 min, p < 0.001). Postoperative complications were lower for robotic (12.5%) and laparoscopic (13.4%) versus open (17.1%, p < 0.001), with […]

This study develops and validates a prognostic model for patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib. Identified nine key risk factors impacting overall and progression-free survival, including tumor number and extrahepatic metastases. Survival prediction model showed area under the curve values of 0.706 at 3 years for overall survival and […]

Evaluating nutrition and body composition can enhance post-surgery success in pancreaticoduodenectomy. 57.2% of patients achieved a textbook outcome, with no 30-day mortality. Key risk factors for not achieving a textbook outcome include age ≥75, malnutrition, and a high visceral fat to muscle ratio. Focusing on these factors preoperatively may significantly improve patient outcomes and overall […]

Early-stage pancreatic cancer outcomes hinge on lymph node counts, affecting surgical decisions. Optimal examined lymph nodes for best survival in stage I and II is ≥10. Stage II patients benefit most with ≥12 examined lymph nodes; ≥7 for T3N0M0 cases. An examined lymph node to regional node positive ratio of ≥9 leads to optimal survival […]

Three-dimensional imaging technology may enhance surgical selection for neoadjuvant-treated pancreatic cancer patients. The 3D-PANC study compares 3D-MSP imaging accuracy to conventional CT in assessing vascular involvement. CT has significantly low accuracy in predicting which patients benefit from surgical resection. This could lead to improved patient outcomes by better identifying surgical candidates. The study will use […]

Triple therapy regimens significantly improve surgical candidacy for patients with unresectable hepatocellular carcinoma. Conversion to surgery rates (CSR) rise from 6% with conventional therapy to 41% with a combination of drug-eluting beads TACE, HAIC, TKI, and immune checkpoint inhibitor. Dual therapies yield lower CSRs (up to 15%) compared to triple therapies, emphasizing the need for […]

Dynamic changes in main pancreatic duct (MPD) diameter are key in predicting malignancy risk for patients with MPD-involved IPMN. In a study of 168 patients, 17.8% developed malignancy over a median of 4 years, with an annual incidence of 4.5%. An MPD growth rate of ≥ 2 mm/year emerged as the strongest predictor, with a […]

Surgeons can leverage a simple scoring system to predict new-onset diabetes after distal pancreatectomy, enhancing patient management. 26.9% of non-diabetic patients developed diabetes within 10 months post-surgery. Five key predictors include prediabetes, age ≥65, BMI ≥25, neck/proximal tumor, and concomitant splenectomy. The scoring system stratifies patients into risk categories with 5-year cumulative incidences of 4.4% […]

Switching to piperacillin-tazobactam for prophylaxis significantly lowers surgical site infections and pancreatic fistula rates in open pancreatoduodenectomy. Patients on piperacillin-tazobactam had 30% fewer surgical site infections and pancreatic fistulas compared to those on cefoxitin. The switch is backed by data from over 4,000 patients, with a clear trend toward piperacillin-tazobactam usage increasing. Consider adopting piperacillin-tazobactam […]

Surgical interventions for mucinous cystic neoplasms (MCN) should be more selective based on updated risk factors. The pooled rate of high-grade dysplasia (HGD) or invasive carcinoma (IC) in resected MCNs is just 17%. Cyst size is crucial: a threshold of 65 mm best differentiates high-risk from low-risk lesions. Key risk factors linked to HGD/IC include […]